ASC4REAL: Efficacy and Tolerability Comparison Between ASCEMBL study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib (ASC) in CML Patients Beyond 2 TKIs

Poster Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Chronic Myeloid Leukemia (CML)
Presenter: Anchit Khanna, MMed.Sci., M.D., Ph.D.
Affiliation: Novartis Australia, Sydney, NSW, Australia
Presentation Date: December 9, 2024
Abstract Number: 4527
Session: Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III
Related content: Chronic Myeloid Leukemia (CML)
Poster Presentation
Abstract Number: 5052
Presenter: Onyee Chan, MD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 9, 2024
Poster Presentation
Abstract Number: 3677
Presenter: Jennifer E Vaughn, MD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 8, 2024
Poster Presentation
Abstract Number: 5192
Presenter: Gaurav Vadnerkar, PhD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 9, 2024
Poster Presentation
Abstract Number: 3812
Presenter: Kejal Jadhav, B.Pharm, MS
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 8, 2024
Poster Presentation
Abstract Number: 1765
Presenter: Jorge E. Cortes, MD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 7, 2024

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.